<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:hpo ids='HP_0003674'>onset</z:hpo> of diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo> is characterised by a rise in albumin excretion rate (AER) and/or a transient rise in glomerular filtration rate (GFR) (hyperfiltration) </plain></SENT>
<SENT sid="1" pm="."><plain>Without intervention AER increases exponentially and there is a linear decrease in GFR after <z:hpo ids='HP_0003674'>onset</z:hpo> of overt <z:hpo ids='HP_0000112'>nephropathy</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>In overt <z:hpo ids='HP_0000112'>nephropathy</z:hpo>, AER is a predictor of decline in GFR and the early AER response to <z:chebi fb="0" ids="35674">antihypertensive</z:chebi> therapy correlates with long-term decline in GFR </plain></SENT>
<SENT sid="3" pm="."><plain>AER can be measured by immunoassay or by other techniques including HPLC </plain></SENT>
<SENT sid="4" pm="."><plain>However, HPLC assays result in higher levels of AER in <z:mpath ids='MPATH_458'>normal</z:mpath> subjects compared with immunoassayable AER </plain></SENT>
<SENT sid="5" pm="."><plain>Recent data suggest that there are distinct albuminuric and non-albuminuric pathways to <z:e sem="disease" ids="C0341697" disease_type="Disease or Syndrome" abbrv="">renal impairment</z:e> in type 1 and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="6" pm="."><plain>In type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, the non-albuminuric pathway may explain a decline in GFR to &lt;60 ml/min/1.73 m(2) in approximately one in four subjects after accounting for the use of renin angiotensin system inhibitors </plain></SENT>
<SENT sid="7" pm="."><plain>In established <z:hpo ids='HP_0000112'>nephropathy</z:hpo> (<z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0022658" disease_type="Disease or Syndrome" abbrv="">kidney disease</z:e> (CKD) stages 3 and 4), plasma cystatin C based estimates of GFR are marginally superior to <z:chebi fb="0" ids="16737">creatinine</z:chebi> based estimates </plain></SENT>
<SENT sid="8" pm="."><plain>However, cystatin C clearly outperforms <z:chebi fb="0" ids="16737">creatinine</z:chebi> based estimates of GFR decline at GFR levels &gt;60 ml/min/1.73 m(2) (CKD stages 1 and 2) </plain></SENT>
<SENT sid="9" pm="."><plain>Other potential markers of progression of diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo> include transforming growth factor beta (TGFbeta) and connective tissue growth factor (CTGF) </plain></SENT>
<SENT sid="10" pm="."><plain>However, long-term studies are needed to define their roles as markers of progression </plain></SENT>
<SENT sid="11" pm="."><plain>Diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo> is likely to be more susceptible to intervention at an early stage and accurate estimation of GFR is already possible with cystatin C </plain></SENT>
<SENT sid="12" pm="."><plain>However, improved formulas for estimating GFR based on using <z:chebi fb="0" ids="16737">creatinine</z:chebi> or other markers are still required, because this may still provide the most cost effective approach applicable to existing clinical practice </plain></SENT>
</text></document>